Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients
- PMID: 10784483
- DOI: 10.1176/appi.ajp.157.5.831
Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients
Abstract
Objective: Glycogen synthase kinase-3 (GSK-3) is a protein kinase that is highly abundant in the brain. It is involved in signal transduction cascades of multiple cellular processes, particularly neurodevelopment. In an attempt to explore possible involvement of GSK-3beta in psychiatric disorders, the authors examined its levels in postmortem brain tissue.
Method: Western blot analysis was performed to measure GSK-3beta in the frontal cortex of 14 schizophrenic patients, 15 patients with bipolar disorder, 15 patients with unipolar depression, and 14 normal comparison subjects.
Results: GSK-3beta levels were 41% lower in the schizophrenic patients than in the comparison subjects. Other diagnostic groups did not differ from the comparison subjects.
Conclusions: These results are consistent with the notion that schizophrenia involves neurodevelopmental pathology. It remains to be investigated whether the active fraction of GSK-3beta, or its activity, is also low in frontal cortex of schizophrenic patients and if this is also reflected in other brain regions.
Similar articles
-
Low GSK-3 activity in frontal cortex of schizophrenic patients.Schizophr Res. 2001 Oct 1;52(1-2):101-5. doi: 10.1016/s0920-9964(00)00174-2. Schizophr Res. 2001. PMID: 11595396
-
GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients.Schizophr Res. 2004 Dec 1;71(2-3):377-82. doi: 10.1016/j.schres.2004.02.020. Schizophr Res. 2004. PMID: 15474909
-
Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult.Eur Neuropsychopharmacol. 2005 Jan;15(1):1-11. doi: 10.1016/j.euroneuro.2004.02.003. Eur Neuropsychopharmacol. 2005. PMID: 15572268 Review.
-
GSK-3 parameters in lymphocytes of schizophrenic patients.Psychiatry Res. 2002 Sep 15;112(1):51-7. doi: 10.1016/s0165-1781(02)00191-9. Psychiatry Res. 2002. PMID: 12379450
-
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.Eur Neuropsychopharmacol. 2002 Feb;12(1):13-25. doi: 10.1016/s0924-977x(01)00131-6. Eur Neuropsychopharmacol. 2002. PMID: 11788236 Review.
Cited by
-
GSK3β and mTORC1 Represent 2 Distinct Signaling Markers in Peripheral Blood Mononuclear Cells of Drug-Naive, First Episode of Psychosis Patients.Schizophr Bull. 2022 Sep 1;48(5):1136-1144. doi: 10.1093/schbul/sbac069. Schizophr Bull. 2022. PMID: 35757972 Free PMC article.
-
S-SCAM inhibits Axin-dependent synaptic function of GSK3β in a sex-dependent manner.Sci Rep. 2022 Mar 8;12(1):4090. doi: 10.1038/s41598-022-08220-1. Sci Rep. 2022. PMID: 35260764 Free PMC article.
-
Analytical Value of Cell-Free DNA Based on Alu in Psychiatric Disorders.Front Psychiatry. 2020 Jan 21;10:992. doi: 10.3389/fpsyt.2019.00992. eCollection 2019. Front Psychiatry. 2020. PMID: 32038328 Free PMC article.
-
The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions.J Biomed Sci. 2018 Oct 4;25(1):71. doi: 10.1186/s12929-018-0473-x. J Biomed Sci. 2018. PMID: 30285728 Free PMC article. Review.
-
Clozapine as a Model for Antipsychotic Development.Neurotherapeutics. 2017 Jul;14(3):750-761. doi: 10.1007/s13311-017-0552-9. Neurotherapeutics. 2017. PMID: 28653280 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
